Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies

Clinical Transplantation

Volumn 20, Issue 4, 2006, Pages 461-464

  Vaidya, Smita ^a   Partlow, David ^a   Barnes, Titus ^a   Thomas, Phillip ^a   Gugliuzza, Kristin ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Acute rejection; Panel reactive antibodies; Renal transplantation; sCD30

Indexed keywords

CALCINEURIN INHIBITOR; CD30 ANTIGEN; HLA ANTIBODY;

ADULT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE;

ANTIGENS, CD; ANTIGENS, CD30; B-LYMPHOCYTES; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; REOPERATION; RETROSPECTIVE STUDIES; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 33745589757     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2006.00506.x     Document Type: Article

References (11)

1. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 2003: 3: 1488.
2. Gebel HM, Bray RA, Ruth JA et al. Flow PRA to detect clinically relevant HLA antibodies. Transplant Proc 2001: 33: 477.
3. Kerman RH, Gebel HM, Bray RA et al. HLA antibodies and donor reactivity define patients at risk for rejection or graft loss. Am J Transplant 2002: 2: 258.
4. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.
5. Pellegrini P, Berghella AM, Costasta I, Adorno D. CD30 antigen: Not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transplant Immunol 2003: 12: 49.
6. Del Prete G, Decarli M, D'Elios MM et al. CD30- mediated signaling promotes the development of human T helper type 2-like T cells. J Exp Med 1995: 182: 1655.
7. Cinti P, Pretagostini R, Arpino A et al. Evaluation of pretransplant immunologis status in kidney-transplant recipients by panel reactive antibody and soluble 30 determinants. Transplantation 2005: 79: 1154.
8. Susal C, Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002: 73: 1269.
9. Pelzl S, Opelz G, Wiesel M et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002: 3.
10. Susal C, Pelzl S, Dohler B, Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002: 1650.
11. Rajakariar R, Jivanji N, Varagunam M et al. High pre-transplant soluble CD30 levels are predictive of the grade of rejection. Am J Transplant 2005: 5: 1922.